Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.67 |
| ▸ | MAOB | P27338 | 8/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | CALML3 | P27482 | 1/20 | 0.44 |
| ▸ | SDHA | P31040 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3043201 | 0.89 | MAOA (0.53) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL3029388 | 0.83 | MAOA (0.46) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL3038122 | 0.81 | MAOA (1.00) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL3031991 | 0.81 | MAOA (0.82) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5765718 | 0.81 | MAOA (0.82) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL4378718 | 0.81 | MAOA (0.71) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL3029035 | 0.79 | MAOA (0.76) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL3043259 | 0.79 | MAOA (0.40) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL3036167 | 0.79 | MAOB (0.60) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL3041712 | 0.77 | MAOA (0.39) | MAOAMAOBLMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919329-B2 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY (US) | 2005-07-19 | — | — | US | claimed |
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | claimed |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-03-04 | — | — | US | claimed |
| US-7645781-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER INC (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | THOMAS RICHARD C | 2007-01-18 | — | — | US | disclosed |
| US-7141588-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| US-6919329-B2 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | disclosed |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | MAOA 957/4885MAOB 976/4885LMNA 3385/4885 |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | MAOA 957/4885MAOB 976/4885LMNA 3385/4885 |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | MAOA 957/4885MAOB 976/4885LMNA 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.